Equillium Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.4%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.21next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly61.3MTarget: Sufficient to fund planned operations into 2029
Quarterly Net Loss Quarterly-5.3MTarget: Narrowing loss through disciplined R&D spending
Quarterly R&D Expenses Quarterly3MTarget: Optimized spending following clinical wind-downs
Watch Items
- EQ504 Phase 1 Proof-of-Mechanism Study InitiationTrigger: Initiation scheduled for mid-2026Action: Monitor clinical trial registry updates and official press releases for first-patient-dosed milestones.
- EQ504 Phase 1 Proof-of-Mechanism Study Data ReadoutTrigger: Data expected approximately six months post-initiation (early 2027)Action: Evaluate safety, tolerability, and biomarker-driven target engagement data to validate the AhR mechanism.
- EQ302 Pipeline AdvancementTrigger: Preclinical progress and IND-enabling preparationsAction: Track development timelines for celiac disease and other gastrointestinal indications.
Research as of 19 Jun 2026